U.S. stock market midday update: Polaryx Therapeutics down 14.83%, market volatility intensifies, capital flow attracts attention

U.S. Stock Market Midday Update Polaryx Therapeutics fell 14.83%. There have been no significant news recently; trading is active with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news Stocks with High Trading Volume in the Industry Gilead Sciences rose 6.11%. Based on recent key news: On February 11, Gilead Sciences announced its fourth-quarter results, with adjusted earnings per share of $1.86, exceeding analysts' expectations of $1.81. Quarterly revenue grew 5% to $7.9 billion, driving the stock price up. Source: Zhitong Finance On February 11, Gilead Sciences announced a quarterly dividend increase of 3.8% to $0.82 per share, boosting investor confidence and raising the stock price. Source: Wall Street Insight On February 12, RBC Capital raised Gilead Sciences' target price from $103 to $118, reflecting market optimism about the company's future growth, with the stock price hitting a 52-week high. Source: Jinshi Data. The biopharmaceutical industry is performing strongly, with significant capital inflow. AbbVie fell 1.09%. Based on recent news: On February 11, AbbVie's price-to-earnings ratio is below the average level of the biotechnology industry, which may indicate that the company is undervalued but could also reflect lower investor expectations for its future growth. This factor may lead to a decline in the stock price. On February 10, market analysts believe there are five stocks more worthy of purchase than AbbVie, despite AbbVie's current rating being "Moderate Buy." This news may weaken investor confidence, leading to a drop in the stock price. On February 10, AbbVie reached a "Most Favored Nation" agreement with the U.S. government, committing to price reductions on certain drugs in exchange for tariff relief and greater policy predictability. This news may have a negative impact on the stock price. The biotechnology industry is generally underperforming, with significant impacts from policy changes. Quince Therapeutics rose 47.19%. Based on recent key news: On February 10, Quince Therapeutics announced the hiring of LifeSci Capital as a financial advisor to help explore restructuring and strategic alternatives. This move may trigger market optimism about the company's future development, driving the stock price up. Source: WSJ On February 10, Quince Therapeutics' stock price rose 91.08% in pre-market trading, despite a 90.71% decline in stock price over the past year. This significant increase may be an example of a "dead cat bounce," indicating that the stock price may not sustain the current level. Source: Benzinga On February 10, technical indicators showed that Quince Therapeutics' stock is in an oversold state, with an RSI of 22.15 and MACD below the signal line, indicating that although the stock may be undervalued, the overall trend remains negative Source: Benzinga The biotechnology industry faces risks of restructuring and strategic adjustments. Stocks ranked at the top of the industry market capitalization Amgen fell 0.15%, with increased trading volume. Based on recent key news: On February 11, Amgen's financial report showed an 8.6% revenue growth, exceeding expectations by 4.1%, driving the stock price up by 8.2%. This performance outperformed other companies in the same industry, boosting market confidence. On February 10, Amgen received FDA approval for its drug UPLIZNA® for the treatment of patients with myasthenia gravis. This approval may enhance the company's future market share and stimulate stock price fluctuations. On February 10, analyst ratings indicated Amgen as "moderate buy," but it was not included in the top recommended stocks list. This rating may affect investor confidence, leading to slight stock price fluctuations. The treatment sector performed poorly, with significant stock price volatility